Arcellx
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
💼Healthcare, Healthcare, Healthcare
👥201-500
📍Gaithersburg
Arcellx
About Arcellx
Arcellx is a clinical stage biotechnology firm focused on developing innovative immunotherapies that aim to revolutionize cell therapy for the treatment of cancer and autoimmune diseases.
Arcellx news and updates
Arcellx, Inc. will invest into assets : stake in Arcellx in the amount of $19.4M on Jan 1st 23'.
During the first three months of the year, Arcellx, Ltd. purchased an additional stake in Arcellx for approximately $19,360,000.
Oct 28, 2022 | beststocks.comArcellx, Inc. is developing CART-ddBCMA
Arcellx has been developing CART-ddBCMA as a treatment for relapsed or refractory multiple myeloma.
Dec 9, 2022 | medcitynews.comArcellx, Inc. is developing Arcellx’s lead Phase 2 program CART-ddBCMA for multiple myeloma
Piper Sandler analysts adjusted the rating after the company and Arcellx entered into a collaboration to develop and commercialize Arcellx’s lead Phase 2 program CART-ddBCMA for multiple myeloma.
Dec 12, 2022 | pulse2.comKite Pharma, Inc. partners with Arcellx, Inc.
Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients.
Dec 12, 2022 | pharmaceutical-technology.com